Back to NVSView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Type 2 Idiopathic Macular Telangiectasia
View Full LandscapeDrug Information
Target Indication
Type 2 Idiopathic Macular Telangiectasia
Clinical Trial
NCT00504400Last updated: 9/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Mometasone furoate/formoterol (MF/F) combinationPhase 3
Chronic Obstructive Pulmonary Disease (COPD)
androgen deprivation therapyPhase 3
Metastatic Cancer
Aflibercept 2 mgPhase 3
Neovascular Age-related Macular Degeneration
Fluticasone/salmeterolPhase 3
Chronic Obstructive Pulmonary Disease
anthracycline ((daunorubicin or idarubicin): Induction Phase onlyPhase 3
Acute Myeloid Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts